BioNTech

#BioNTech #Head and neck cancer #Immunotherapy #mRNA #Phase III trial

BioNTech’s mRNA immunotherapy fails to meet primary endpoint

BioNTech has announced the first topline results from the AHEAD-MERIT Phase II/III clinical trial for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or tenu-ra).  The clinical trial is evaluating BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent… Read More

#Cancer Research #News

BioNTech HQ
#BioNTech #Drug discovery #mRNA

BioNTech co-founders launch new mRNA company

An independent company is to be established and led by BioNTech co-founders Professor Ugur Sahin and Professor Özlem Türeci to “advance next-generation mRNA innovations”.   BioNTech has announced plans to contribute related rights and mRNA technologies to the new company to support the prioritised development of mRNA innovations… Read More

#Business & Investment #News

Lung cancer
#BioNTech #Bristol Myers Squibb #Lung cancer #Oncology #Phase II trial

Bispecific antibody trial shows encouraging antitumour activity

BioNTech and Bristol Myers Squibb have revealed global interim Phase II data for their PD-L1xVEGF-A bispecific antibody pumitamig in patients with extensive-stage small cell lung cancer (ES-SCLC) which shows encouraging antitumour activity.  The data for pumitamig plus chemotherapy showed a 76.3% confirmed objective response rate (cORR), 100%… Read More

#Cancer Research #News

#BioNTech #CureVac #Immunotherapy #Mergers and acquisitions #mRNA #Oncology

BioNTech boosts mRNA expertise with CureVac acquisition

Following a definitive Purchase Agreement, BioNTech has announced its intention to acquire all of the shares of fellow German company CureVac.  With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapies.  The company’s oncology strategy focuses on… Read More

#Business & Investment #News

#BioNTech #Cancer immunotherapy #Cancer vaccine #European Commission #Immunology / Virology & Vaccines #mRNA #University College London Hospitals

First patient dosed in UK novel cancer vaccine trial

A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.  It is the first time this immunotherapy made by BioNTech will be studied in a clinical… Read More

#Cancer Research #News

RNA
#3D printing #BioNTech #Partnership #RNA Therapeutics #Triastek

BioNTech and Triastek team up to create 3D printed RNA therapeutics

BioNTech and Triastek have entered into a research collaboration and platform technology license agreement to develop RNA therapeutics for oral delivery based on 3D printing technology. The collaboration aims to provide groundbreaking therapies to address unmet medical needs in an easy to administer oral formulation. Read More

#Business & Investment #News

Vaccine
#BioNTech #Cancer vaccine #Clinical trials #mRNA #Oncology #UK

NHS England launches country-wide cancer vaccine trials

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments. The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are… Read More

#Cancer Research #News #Trending News

#AI / data analytics / healthtech / informatics #Big pharma #BioNTech #Biopharmaceuticals #Comirnaty #Covid-19 #Drug discovery #Healthcare #Moderna #mRNA #Pfizer

New podcast on drug discovery trends

This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and… Read More

#News

Close up of vaccine syringe
#BioNTech #Comirnaty #Covid-19 #Covid-19 vaccine #MHRA #Omicron #Pfizer

UK regulator approves Pfizer/BioNTech’s adapted Covid-19 vaccine

Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has… Read More

#News #Trending News

Preparing Covid-19 vaccine for injection
#BioNTech #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Moderna #Novavax #Pfizer #Vaccines

New Covid-19 vaccines ready to slow spread of EG.5

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated… Read More

#News #Trending News

Lipid nanoparticle mRNA vaccine
#Arcturus #BioNTech #Covid-19 vaccine #Moderna #mRNA #mRNA-based vaccines

The companies taking the lead on mRNA

DDW’s Diana Spencer takes a closer look at three companies hoping to be the first to bring new mRNA therapeutics to the market. Although the concept of using mRNA to make therapeutics or vaccines has been around for decades, it took the urgency of a global… Read More

#Exclusive Content

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. … Read More

#Business & Investment #Cancer Research #News #Trending News

#BioNTech #Covid-19 #Moderna #Pfizer

Moderna sues Pfizer/BioNTech over Covid patent

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty… Read More

#Covid-19 #News

#BioNTech #Covid-19 #Immunology / Virology & Vaccines #mRNA

BioNTech to deliver prestigious lecture on mRNA  

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19.   The lecture will be delivered in two halves by Uğur Şahin and Özlem Türeci, co-founders of… Read More

#News